- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Immune Antibody Preparation Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- Novel Cancer Therapeutic Strategy: Development of Bispecific Antibody-Drug Conjugates
- Nveiling the Molecular and Immunological Drivers of Antibody-Drug Conjugates (ADCs) in Cancer Treatment
- A PBD Dimer-Containing Antibody-Drug Conjugate (KK2845) Targeting TIM-3-Expressing AML
- A Novel Approach for Cancer Therapy - Modulating TCR Complex Recruitment to the T Cell Antigen Coupler (TAC) Enhances TAC-T Cell Function
- Development of Therapeutic Monoclonal Antibodies for Disease Treatment
- Common Problems and Solutions of Prokaryotic Expression of Recombinant Protein
- Neutralizing Monoclonal Antibody Development Service FAQ
- A Brief Discussion on Prokaryotic Expression of Recombinant Antibodies
- Common Problems and Solutions for Recombinant Antibody Yeast Expression Experiments
- Common Problems and Solutions for Recombinant Antibody Expression Experiments in lactation
Special topic on antibody modification
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
- Overview of Yeast Two Hybrid System Principle and Application
- Introduction to Yeast Display Antibody Screening Technology
- Overview of Yeast Display Technology
- Overview of Yeast Two Hybrid Technology
- Yeast Display Platform for Rapid Nanobody Discovery
- What is the essential difference between antibody phage display and yeast display?
- Yeast One Hybrid FAQ
Yeast Display Technology Special Topic
- Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?
- Yeast Hybrid Library Construction: Smart Technology
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
- Antibody Affinity Test EC50
- Antibody Full Length Sequencing
Antibody Detection Service Topic
- Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model
- Non-Invasive In Vivo Monitoring of PROTAC-Mediated Protein Degradation Using an Environment-Sensitive Reporter
- How do you know Phage Display Peptide Library?
- Phage Display Peptide Library
- Phage Display Antibody Library Technology
- Efficient Screening Methods and Research Progress of Anti-tumor Polypeptides
- Molecular Screening and Application of Targeted Peptides
- Screening Strategies for Cyclic Peptide Drugs
- Construction Method of Random Peptide Library
- Construction and Screening of Peptide Library
Special Topic on Phage Display Technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Molecular Biology Service Topics
-
Product Center
- Contact Us
Tek Biotech has a complete recombinant antibody expression production platform, rich experience in recombinant protein and recombinant antibody expression. Based on phage display technology, we can provide customers with high-quality recombinant antibody preparation and screening services.
Based on the phage display technology platform, Tekbiotech can provide major experimental links including antigen design, alpaca immunization, library construction and screening, and active function verification, and provide highly specific and high-affinity camelid VHH antibodies to scientists around the world.
Tek Biotech has complete upstream and downstream docking services, including antigen, antibody expression and purification, antibody humanization, recombinant antibody expression and other services, and can provide VHH screening, scFv sequence screening, Fab antibody screening, etc. to meet the different needs of different customers.
TechBio has a stable mammalian CHO cell and prokaryotic cell nanoantibody expression platform, and can provide customers with one-stop services from antibody sequence analysis, linker design, label selection design, vector selection design to exploration and optimization of recombinant nanoantibody expression conditions, recombinant antibody purification, etc.
Based on the phage display technology platform, Tek Biotech can provide major experimental links including antigen design, alpaca immunization, library construction and screening (solid/liquid screening), and active function verification, and provide highly specific and high-affinity camelid VHH antibodies to scientists around the world.
Tek Biotech has a deep knowledge reserve in antibody research and development. Our scientists can provide customers with more systematic antibody downstream engineering services, including antibody purification, antibody pairing (ELISA custom development), antibody-antigen binding kinetics research, antibody sequencing and antibody modification, etc. One-stop technical services, saving customers valuable time and money.
Tek Biotech has mature antibody humanization technology, which can humanize antibody sequences and ensure that the affinity of the modified humanized antibodies remains at the same order of magnitude. We provide guaranteed humanization services to facilitate your experiments.
TekBiotech has established a complete and mature phage antibody display technology platform. Based on the phage display technology platform, TekBiotech can provide major experimental links including antigen design, alpaca immunization, library construction and screening, and active function verification, and provide highly specific and high-affinity camelid VHH antibodies to scientists around the world.
Tek Biotech provides antibody phage display technology and yeast display technology, using its professional team and advanced laboratory equipment to help customers screen antibodies with high affinity and high specificity.
With its deep expertise and resources in nanoantibody research and development, Tek Biotech is committed to providing customers with quality services, especially in the key technology of alpaca immunization. Our self-developed adjuvants are carefully optimized for the alpaca immune system to ensure that they have a potency and specificity that exceeds traditional adjuvants.
